Celldex Therapeutics, Inc. (CLDX) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$38.44

From 52W high−14.78%

Volume2.06M

Market cap$3.00B

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataSep 18, 2026

Open

$38.44

From 52W high

−14.78%

Volume

2.06M

Market cap

$3.00B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−7.7x

P/E (TTM)

—

RSI (14)

42.7

MomentumView details →

1D Return

−1.90%

YTD Return

+39.21%

SummaryUpdated Jun 1, 2026

Celldex Therapeutics, Inc. (NASDAQ:CLDX) is a biopharmaceutical company founded in 1983 and headquartered in Hampton, New Jersey. The company went public in 1986 and has spent nearly four decades developing innovative antibody-based therapies for cancer and inflammatory diseases. Celldex specializes in creating monoclonal and bispecific antibodies, which are sophisticated protein-based drugs designed to target specific disease mechanisms with high precision. The company operates as a clinical-stage biotechnology firm, meaning its drug candidates are currently undergoing human testing but have not yet received regulatory approval for commercial sale.

Ask drillr about Celldex Therapeutics, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−7.7x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

4.2x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−42.07%

ROA (TTM)

−38.42%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

−98.07%

EPS YoY

−44.85%

FCF YoY

−29.09%

Revenue CAGR 3Y

−13.98%

EPS CAGR 3Y

−59.18%

EBITDA YoY

−38.10%

MomentumView details →

1D Return

−1.90%

YTD Return

+39.21%

1Y Return

+53.64%

RSI (14)

42.7

vs 50D SMA

−3.33%

vs 200D SMA

+17.71%

Capital & dividendView details →

Debt/Equity

0.01x

Current Ratio

11.82x

Quick Ratio

11.82x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.94

EPS Surprise

11.32%

Beats (12Q)

6/12

Next Q EPS Est

−$1.02

Avg Surprise (4Q)

−3.09%

Rev Surprise

−97.01%

Financials snapshotView financials →

Revenue (TTM)

112000.00

Net Income (TTM)

−300.59M

Op. CF (TTM)

−235.57M

Next earningsNov 9, 2026 →

Latest newsMore news →

Celldex Therapeutics reported its Q2 2026 financial results, with revenue of $22,000 and a net loss of $73.5 million.46d ago

Celldex reported Phase 2 study results for barzolvolimab in prurigo nodularis that did not meet primary and key secondary endpoints.61d ago

Similar companies

MBX Biosciences, Inc. Common StockMBX Jiangsu Recbio Technology Co., Ltd.02179.HK 蔚蓝生物603739.SH uniQure N.V.QURE 寿仙谷603896.SH Medtide Inc.03880.HK Find similar companies →

Latest newsMore news →

Celldex Therapeutics reported its Q2 2026 financial results, with revenue of $22,000 and a net loss of $73.5 million.46d ago Celldex reported Phase 2 study results for barzolvolimab in prurigo nodularis that did not meet primary and key secondary endpoints.61d ago